1. Volume 145, Issue 4, Pages 790-800.e3 (October 2013)
Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection 
Patrick Marcellin, Curtis Cooper, Luis Balart, Dominique Larrey, Terry Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman, Emily Labriola–Tompkins, Sophie Le Pogam, Isabel Nájera, Denise Thomas, Gregory Hooper, Nancy S. Shulman, Ying Zhang, Mercidita T. Navarro, Chin Yin Lim, Michael Brunda, Norah A. Terrault, Ellen S. Yetzer 
Gastroenterology 
Volume 145, Issue 4, Pages e3 (October 2013)
DOI: /j.gastro
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1 ATLAS study design.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Patient disposition, including reasons for premature withdrawal from treatment.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
Virologic response rates, sustained virologic response (SVR) and relapse rates (modified intention-to-treat analysis).
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Sustained virologic response (SVR) rates (A) by IL28B genotype (CC vs non-CC). Does not include 55 patients with unknown/undetermined IL28B genotypes. (B) by HCV subgenotype (1a vs 1b). Does not include 3 patients with unknown/other HCV subgenotypes.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Mean HCV RNA levels during 24 weeks of treatment
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions